Weekly Nephrology Journal Summary
29 August–4 September 2026 | Verified sources | Concise clinical review
This week’s clinical focus
CKD risk stratification, dialysis cardiovascular physiology, anemia, transplant immunology, pediatric kidney care, xenotransplantation, and donor follow-up.
Safety and clinical outcomes of antithrombotic therapy in children and young adults with kidney failure on dialysis: a 10-year single-center retrospective cohort study.
AI Clinical Summary
In 77 patients younger than 23 years receiving dialysis, 33 received antithrombotic therapy. Bleeding occurred in 3 treated patients (9.1%) and recurrent thrombosis in 5 (15.2%); most recurrences involved documented non-adherence or treatment discontinuation. The single-center observational design and small sample require cautious interpretation, but the findings support individualized prescribing with close adherence and bleeding surveillance.
Clinical relevance: High
View original article →
Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial.
AI Clinical Summary
In the CREDENCE population of 4,401 patients with type 2 diabetes and CKD, canagliflozin’s kidney and cardiovascular benefits were consistent across no polypharmacy, polypharmacy, and hyperpolypharmacy groups. Absolute reductions in hospitalization and cardiovascular events were estimated to be larger with greater medication burden. This supports not excluding indicated SGLT2-inhibitor therapy solely because of polypharmacy.
Clinical relevance: High
View original article →
Crescents in native kidney biopsies from patients with IgA nephropathy and the risk of recurrence after kidney transplantation: a retrospective cohort study, systematic literature review and meta-analysis of observational studies.
AI Clinical Summary
Across a Lausanne cohort and five additional observational cohorts totaling 311 transplant recipients with IgA nephropathy, crescents in the native biopsy were not associated with recurrent IgA nephropathy in the allograft (RR 1.53, 95% CI 0.40–5.90). Crescents remain prognostically unfavorable for native-kidney progression, but should not be treated as a stand-alone predictor of post-transplant recurrence.
Clinical relevance: Moderate
View original article →
Porcine kidney xenotransplantation as a bridge to allotransplantation: a first-in-human study.
AI Clinical Summary
A gene-edited porcine kidney provided dialysis independence for 271 days before graft failure from microvascular injury and thrombotic microangiopathy. The recipient had no detected porcine pathogen transmission, no clinically significant HLA sensitization, and later received a human kidney with immediate function. This is an important feasibility signal, not evidence of established long-term xenograft efficacy or safety.
Clinical relevance: High
View original article →
Randomized Controlled Trial Comparing Lactoferrin Plus Iron to Iron Alone for Iron Deficiency Anemia in CKD.
AI Clinical Summary
Among 185 patients with iron-deficiency anemia and CKD, oral lactoferrin added to iron produced larger 3-month hemoglobin increases than iron alone in both nondialysis and dialysis groups, with generally greater improvements in iron indices. Inflammatory-marker effects were inconsistent. The short, open-label trial supports further evaluation rather than replacing established anemia treatment pathways.
Clinical relevance: Moderate
View original article →
Intradialytic Myocardial Stunning in Hemodialysis Dependent End Stage Kidney Disease.
AI Clinical Summary
This review frames intradialytic myocardial stunning as transient dialysis-associated myocardial contractile dysfunction that may contribute to repeated cardiovascular injury. It summarizes proposed mechanisms, incidence, risk factors, and research gaps, including possible overlap with stress cardiomyopathy. The article is hypothesis-generating and does not establish a validated diagnostic threshold or proven intervention.
Clinical relevance: Moderate
View original article →
Lower- Versus Conventional-Sodium Dialysate and Left Ventricular Mass in Patients Receiving Hemodialysis: Causal Analyses of a Randomized Clinical Trial.
AI Clinical Summary
Lower-sodium dialysate reduced interdialytic weight gain but did not reduce left-ventricular mass. Path analysis suggested that fluid volume and blood-pressure pathways were the main determinants of left-ventricular mass, whereas the intervention’s effects on these mediators were insufficient. The analysis informs mechanism; it does not justify changing dialysate prescriptions without individualized clinical assessment.
Clinical relevance: Moderate
View original article →
Long Term Outcomes in Living Kidney Donors Over 30 Years.
AI Clinical Summary
In 1,863 Swiss living kidney donors followed for a median of 12 years, kidney function was broadly stable and only 3 donors progressed to dialysis-dependent kidney failure. The combined adverse endpoint occurred in 2.1%; male sex, age, and predonation obesity were independent predictors. The results support donor safety while reinforcing standardized, long-term surveillance and risk-aware counseling.
Clinical relevance: High
View original article →
The Impact of Non-AKI eGFR Variability on CKD Progression in Individuals With Type 2 Diabetes and Preserved Kidney Function.
AI Clinical Summary
Among 98,322 people with type 2 diabetes and preserved eGFR, greater non-AKI eGFR variability predicted progression to stage G3b CKD. The highest variability quartile had an adjusted hazard ratio of 1.57 versus the lowest. This association is not proof of causality, but supports interpreting repeated kidney-function fluctuations in context rather than relying only on a single eGFR value.
Clinical relevance: High
View original article →
Effects of a telehealth-supported home-based exercise program on functional capacity, sarcopenia risk, and patient-reported outcomes in non-dialysis stage 4-5 chronic kidney disease.
AI Clinical Summary
In 51 completers with stage 4–5 nondialysis CKD, a 12-week telehealth-supported home exercise program improved 6-minute-walk distance compared with usual care (+29.4 versus −19.3 m; P<0.001), alongside improvements in sarcopenia risk, fatigue, mood, sleep, physical performance, and quality of life. The small trial supports feasibility, but broader implementation and longer-term outcome data are needed.
Clinical relevance: Moderate
View original article →